Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This revolutionary drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By boosting these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultima